JW Pharmaceutical Corp. (formerly Choongwae Pharma) is one of the leading pharmaceutical companies in Korea with core competencies in antibiotics, IV solutions, and anti-cancer treatments. JW is currently exploring targeted therapies in oncology leveraging the collaborative research and development strengths from the JW Drug Discovery Center in Korea and the JW Theriac Corp in the US. This R&D pipeline is driven by our platform technologies that have the potential to eradicate cancer stem cells selectively through a molecularly targeted approach. ------- JW Group consists of JW Holdings, JW Pharmaceutical, JW Medical, JW ShinYak, JW Industrial, JW Life Science, and JW Creagene. JW possesses i) magnificent sales force (900 reps) for the hospital market, ii) strong relationships with managements of hospitals & and hospital pharmacies, iii) excellent rapport with key opinion leaders in endocrinology, gastroenterology, oncology, cardiology, nephrology, urology and the general surgery therapeutic areas. JW's total sales revenue of US $ 0.7 billion was derived from Korea and other several Asian countries in 2012